이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

2026년 8월 7일 업데이트: Rigel Pharmaceuticals

A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors

An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors

연구 개요

연구 유형

중재적

등록 (추정된)

12

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Must be willing and able to participate and comply with all study requirements and to provide signed and dated written informed consent
  • Adult male or female ≥ 18 years of age at the time of signing the informed consent form.
  • Must have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m² and a minimum body weight of 50 kg at screening.
  • Must have an Eastern Cooperative Oncology Group performance status ≤ 2.
  • Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)
  • Must have a confirmed diagnosis of advanced or metastatic solid tumor that has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.
  • Must have adequate organ function, defined by the following:

    1. Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L.
    2. Platelet count ≥ 75 × 10⁹/L.
    3. Hemoglobin ≥ 9 g/dL.
    4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with known liver metastases.
    5. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in patients with Gilbert syndrome).
    6. Creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation.
    7. Serum phosphorus ≤ 5.5 mg/dL.
    8. International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) within normal laboratory limits.
  • Must be at least 4 weeks from major surgery, radiotherapy, chemotherapy, immunotherapy, kinase/targeted therapy, or gene therapy prior to the first dose of study treatment and recovered from treatment-related toxicities to ≤ Grade 1 (excluding alopecia). Must be ≥ 6 weeks since last treatment if they received a long-acting agent such as a nitrosourea, mitomycin, or monoclonal antibodies. In general, a treatment interval of two half-lives should be considered and discussed with the Sponsor. (Concurrent cancer therapy of any type is not permitted).
  • Female patients may participate if they are not of childbearing potential (e.g., surgically sterile or postmenopausal).
  • Male patients with female partners of childbearing potential must agree to use highly effective contraception during study treatment and for 90 days after the last dose of study treatment.
  • Male patients must refrain from sperm donation during study treatment and for 90 days after the last dose of study treatment.

Exclusion Criteria:

  • Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at screening that, in the investigator's judgment, are likely to interfere with the objectives of the trial or the safety of the patient.
  • Surgery (e.g., gastric bypass) or medical condition that may significantly affect absorption of study medications, as judged by the investigator.
  • History of pneumonitis within the last 12 months.
  • History of active or latent tuberculosis (TB), regardless of treatment history, or a positive screening test for latent Mycobacterium tuberculosis infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat testing or by a purified protein derivative (PPD) skin test.
  • Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the investigator, could impact patient safety (e.g., COVID-19 or influenza).
  • Clinically significant, uncontrolled cardiovascular disease, including:

    1. New York Heart Association (NYHA) Class III or IV congestive heart failure.
    2. Myocardial infarction or unstable angina within the previous 6 months, clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (e.g., second- or third-degree heart block).
    3. Uncontrolled hypertension (i.e., mean systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg on 3 repeated measurements) or clinically significant hypotension (i.e., systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg) or severe episodes of orthostatic hypotension.
    4. History of prolonged QT syndrome or torsades de pointes, or familial history of long QT syndrome.
    5. QTcF ≥470 ms on at least 2 ECGs performed >30 minutes apart.
  • Central nervous system (CNS) metastases or primary CNS tumor.
  • Use of systemic corticosteroids within 4 weeks prior to first dose of study treatment.
  • More than 30 Gy of radiotherapy to the lung within 6 months prior to check-in.
  • History of multiple and/or severe allergies to drugs or foods, or history of severe anaphylactic reaction.
  • Use of prohibited medications or procedures
  • Medical conditions, treatments, or underlying diseases that constitute contraindications to the use of study substrates or probe drugs
  • Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.
  • Participation in another investigational drug trial within 30 days prior to study drug administration (or within 5 half-lives of the investigational drug, whichever is longer) or exposure to more than 3 investigational agents within 12 months prior to study drug administration.
  • Positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening (a negative PCR test overrides a positive serology).
  • Positive human immunodeficiency virus (HIV) test at screening.
  • Positive urine drug screen (unless attributable to concomitant medication) or positive alcohol breath test at screening and/or Day -1.
  • Patients who are legally incapacitated, have limited legal capacity, or are otherwise considered vulnerable.
  • Female patients who are pregnant or breastfeeding.
  • Patients who plan to become pregnant or father a child (including ova or sperm donation) during the study or within 3 months after the last dose of study drug.
  • Known allergy or history of hypersensitivity to study drug(s) or their excipients.
  • Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
  • Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
  • History of or active clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatologic, hematologic, or other disorder that, in the investigator's judgment, could interfere with study participation or the absorption, metabolism, or excretion of study treatment.
  • History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Pralsetinib with CYP450 Probe Substrates and Hormonal Contraceptive
Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33
Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)
기간: Up to 48 hours post-dose or as appropriate for each probe substrate
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9, probe substrates, and hormonal contraceptive by measuring AUC0-inf for each probe substrate and its relevant metabolites.
Up to 48 hours post-dose or as appropriate for each probe substrate
Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)
기간: Up to 48 hours after each probe drug administration
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9 probe substrates, and hormonal contraceptive by measuring AUClast for each probe substrate and its relevant metabolites.
Up to 48 hours after each probe drug administration
Maximum Peak Plasma Concentration (Cmax)
기간: Up to 48 hours after each probe drug administration
To evaluate how pralsetinib affects the peak levels of probe substrates, and hormonal contraceptive, in the blood after they are taken alone and again after treatment with pralsetinib
Up to 48 hours after each probe drug administration

2차 결과 측정

결과 측정
측정값 설명
기간
Time to Maximum Plasma Concentration (tmax)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the time required to reach peak plasma concentration for each probe drug.
Up to 48 hours after each probe drug administration
Terminal Half-Life (t½)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization To evaluate the effect of pralsetinib on the terminal half-life of each probe drug
Up to 48 hours after each probe drug administration
Percent of Area Under the plasma concentration-time curve obtained at extrapolation (%AUCex)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to determine the proportion of the AUC that is extrapolated, providing insight into pralsetinib's effect on drug elimination
Up to 48 hours after each probe drug administration
Mean residence time (MRT)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the average time each probe drug remains in the body
Up to 48 hours after each probe drug administration
Terminal Elimination Rate Constant (λz)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the terminal elimination rate constant of each probe drug
Up to 48 hours after each probe drug administration
Apparent Total Body Clearance (CL/F)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to evaluate the effect of pralsetinib on the apparent total body clearance of each probe drug
Up to 48 hours after each probe drug administration
Apparent Volume of Distribution (Vz/F)
기간: Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib influences the apparent volume of distribution of each probe drug
Up to 48 hours after each probe drug administration
Safety and Tolerability
기간: From the start of treatment through approximately 30 days after the last dose of study treatment
Incidence, frequency, relatedness, and severity of treatment-emergent adverse events (TEAEs) associated with co-administration of pralsetinib and probe substrates
From the start of treatment through approximately 30 days after the last dose of study treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 4일

기본 완료 (추정된)

2027년 7월 30일

연구 완료 (추정된)

2027년 8월 30일

연구 등록 날짜

최초 제출

2026년 7월 9일

QC 기준을 충족하는 최초 제출

2026년 7월 9일

처음 게시됨 (실제)

2026년 7월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 7일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다